What is NanoHybrids?
NanoHybrids operates at the intersection of nanotechnology and molecular medicine, providing high-precision gold nanospherical and nanorod particles. Their product suite is engineered to facilitate breakthroughs in photoacoustic imaging, photothermal therapy, and lateral flow assays. By enabling non-invasive detection of diseased tissue, the company provides essential tools for researchers and clinicians aiming to improve diagnostic accuracy. Their commitment to molecular targeting positions them as a key enabler in the development of next-generation medical interventions, bridging the gap between laboratory research and practical clinical application.
How much funding has NanoHybrids raised?
NanoHybrids has raised a total of $225K across 1 funding round:
Grant
$225K
Grant (2016): $225K with participation from National Cancer Institute
Key Investors in NanoHybrids
National Cancer Institute
The National Cancer Institute is a federal agency dedicated to reducing the prevalence of cancer through rigorous research into cancer biology, prevention strategies, and the development of innovative clinical interventions.
What's next for NanoHybrids?
With the support of its recent financing, NanoHybrids is poised to expand its operational capacity and deepen its research into molecular targeting. The strategic roadmap likely involves scaling production capabilities to meet the growing demand for high-stability nanoparticles in the life sciences sector. Furthermore, the company is expected to leverage its current market position to forge deeper partnerships within the oncology and diagnostic imaging fields. By prioritizing innovation in photothermal therapy and non-invasive detection, NanoHybrids is well-positioned to capitalize on the increasing global demand for advanced, nanotechnology-driven healthcare solutions, ensuring long-term growth and sustained competitive advantage in a rapidly evolving technological landscape.
See full NanoHybrids company page
